Thursday, 27 December 2018

EGFR-targeting trial or Tagrisso?

Looking at a possible clinical trial for my husband with an ADC (antibody-drug conjugate) called ABBV-321 that targets EGFR.  The trial has identified a maximum dose and is now in the expanded safety phase.  Any one know anything about this?  https://clinicaltrials.gov/ct2/show/NCT03234712

My husband's tumor is showing progression, so if he's deemed eligible for the trial then we'd be choosing between the trial or a combo of CCNU/Avastin/Tagrisso (the latter to target that EGFR amplification).  Choices, choices....


No comments:

Post a Comment